Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with obstructive sleep apnea (OSA).

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ...

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice – Patients switched to donidalorsen without ...

Investing.com -- Viatris Inc. (NASDAQ: VTRS) stock fell 3.6% after the company announced that its Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint. The randomized, double ...

Known for its quick reload and solid design, the Model 3 became a trusted sidearm around the world. Learn how it helped build Smith & Wesson’s legacy.

Biogen initiates phase 3 study of felzartamab in kidney disease patients Approximately 36,000 people in the US are affected by primary membranous nephropathy Biogen has announced that it has initiated ...

PASADENA, Calif., July 08, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company ...

What is today’s moon phase? As of Thursday, July 3, the moon phase is Waxing Gibbous. According to NASA's Daily Moon Observation, 57% of the moon will be lit up and visible to us on Earth.

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later.

A second phase 3 pivotal clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia met its primary and key secondary endpoints, according to a press ...

Opus Genetics reports positive Phase 3 trial results for Phentolamine Ophthalmic Solution 0.75% in treating presbyopia.

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a ...